Ken Griffin Eledon Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$1.54 - $2.13 $11,128 - $15,391
-7,226 Reduced 31.14%
15,982 $32,000
Q4 2023

Feb 14, 2024
BUY
$1.12 - $1.86 $25,992 - $43,166
23,208 New
23,208 $41,000
Q2 2023

Aug 14, 2023
SELL
$1.34 - $2.85 $30,913 - $65,749
-23,070 Reduced 74.88%
7,740 $10,000
Q1 2023

May 15, 2023
BUY
$2.0 - $3.46 $61,620 - $106,602
30,810 New
30,810 $72,000

Others Institutions Holding ELDN

# of Institutions
34
Shares Held
18.4M
Call Options Held
0
Put Options Held
0
View Full List

About Eledon Pharmaceuticals, Inc.

ELDN Quotes by TradingView
  • Ticker ELDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,756,800
  • Market Cap $60M
  • Description
  • Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...
More about ELDN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email